Charles Schwab Investment Management Inc Cti Biopharma Corp Transaction History

Charles Schwab Investment Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$4.2 - $6.01 $12,184 - $17,435	2,901 Added 1.07%	273,002 $1.15 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $55,202 - $76,538	12,405 Added 4.81%	270,101 $1.62 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $89,426 - $123,962	16,684 Added 6.92%	257,696 $1.5 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $722,481 - $1.28 Million	203,516 Added 542.77%	241,012 $1.44 Million
Q3 2021 Nov 16, 2021	BUY	$2.25 - $3.18 $39,366 - $55,637	17,496 Added 87.48%	37,496 $111,000
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $49,600 - $76,000	20,000 New	20,000 $65,000
Q2 2019 Aug 09, 2019	SELL	$0.8 - $1.03 $76,400 - $98,365	-95,500 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$1.72 - $5.24 $24,659 - $75,125	-14,337 Reduced 13.05%	95,500 $207,000
Q2 2018 Aug 08, 2018	BUY	$3.81 - $5.26 $418,478 - $577,742	109,837 New	109,837 $547,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.